Recombinant Human CTLA-4 Fc Chimera His-tag Protein

Name: Recombinant Human CTLA-4 Fc Chimera His-tag Protein
Brand: R&D Systems
SKU: 325-CT
Rating: 5 (5 reviews)

Catalog #: 325-CT
8 Citations 5 Reviews Datasheet / COA / SDS

Carrier Free

Catalog #	Availability	Size / Price	Qty
325-CT-200/CF
325-CT-01M/CF

With Carrier

Catalog #	Availability	Size / Price	Qty
325-CT-200

Recombinant Human CTLA-4 Fc Chimera His-tag Protein Bioactivity

2 Images

All CTLA-4 Proteins and Enzymes

Product Details

Citations (8)

FAQs

Reviews (5)

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human CTLA-4 Fc Chimera His-tag Protein Summary

Product Specifications

Purity

>90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its ability to inhibit IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. Linsley, P.S. et al. (1991) J. Exp. Med. 174:561. The ED₅₀ for this effect is 0.1-0.4 µg/mL when stimulated with 1 µg/mL Recombinant Human B7‑1/CD80 Fc Chimera (Catalog #
140-B1) in the presence of PHA.

Source

Spodoptera frugiperda, Sf 21 (baculovirus)-derived human CTLA-4 protein

Human CTLA-4 (Ala37-Phe162) Accession # Q6GR94	IEGRMD	Human IgG₁ (Pro100-Lys330)	6-His tag
N-terminus			C-terminus

Accession #

Q6GR94

N-terminal Sequence
Analysis

Ala37

Structure / Form

Disulfide-linked homodimer

Predicted Molecular Mass

40 kDa (monomer)

Product Datasheets

325-CT (with carrier)

Product Datasheet

COA

SDS

325-CT/CF (carrier free)

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

325-CT

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution	Reconstitute at 500 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

325-CT/CF

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution	Reconstitute at 200 μg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Bioactivity

View Larger

Recombinant Human CTLA-4 Fc Chimera (Catalog # 325-CT) inhibits IL-2 secretion by stimulated Jurkat human acute T cell leukemia cells. The ED₅₀ for this effect is 0.1-0.4 µg/mL when stimulated with 1 µg/mL Recombinant Human B7-1 Fc Chimera (Catalog # 140-B1) in the presence of PHA.

SDS-PAGE

View Larger

1 μg/lane of Recombinant Human CTLA-4 Fc Chimera was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing single bands at 51 kDa and 94 kDa, respectively.

Reconstitution Calculator

Background: CTLA-4

CTLA-4 (cytotoxic T-lymphocyte-4, designated CD152), is a type I transmembrane T cell inhibitory molecule that is a member of the Ig superfamily (1, 2). Human or mouse CTLA-4 cDNA encodes 223 amino acids (aa) including a 35 aa signal sequence, a 126 aa extracellular domain (ECD) with one Ig-like V-type domain, a 21 aa transmembrane (TM) sequence, and a 41 aa cytoplasmic sequence. It is found as a covalent homodimer of 41‑43 kDa (2). Within the ECD, human CTLA-4 shares 68%, 71% and 83‑86% aa sequence identity with mouse, rat and porcine/bovine/rabbit/feline/canine CTLA-4, respectively. A 174 aa form that lacks TM and cytoplasmic sequences (sCTLA-4) is possibly secreted (3‑5). Isoforms of 56‑79 aa that mainly contain parts of the cytoplasmic domain are reported. In mouse, an isoform lacking the Ig-like domain has ligand-independent inhibitory activity and is termed liCTLA-4 (6). CD28, which is structurally related to CTLA-4, is constitutively expressed on naïve T cells and promotes T cell activation when engaged by B7-2 on antigen-presenting cells (APC) within the immunological synapse (IS) (1, 7, 8). In contrast, CTLA-4 is recruited from intracellular vesicles to the IS beginning 1, 2 days after T cell activation (2, 7, 8). It forms a linear lattice with B7‑1 on APC, inducing negative regulatory signals and ending T cell activation (9). Abatacept, a therapeutic human CTLA-4-Ig fusion protein (trade name Orencia), competes with CD28 for B7-1 and B7-2 binding and has been used to antagonize T cell activation in autoimmune conditions and to enhance transplant survival (10). Mice deleted for CTLA-4 show no abnormalities until after birth, but then develop lethal autoimmune reactions due to continued T cell activation and poor control by regulatory T cells, which constitutively express CTLA-4 in wild-type mice and humans (11‑13).

References

Harper, K. et al. (1991) J. Immunol. 147:1037.
Teft, W.A. et al. (2006) Annu. Rev. Immunol. 24:65.
Magistrelli, G. et al. (1999) Eur. J. Immunol. 29:3596.
Tector, M. et al. (2009) BMC Immunol. 10:51.
Oaks, M.K. and K.M. Hallett (2000) J. Immunol. 164:5015.
Vijayakrishnan, L. et al. (2004) Immunity 20:563.
Pentcheva-Hoang, T. et al. (2004) Immunity 21:401.
Jansson, A. et al. (2005) J. Immunol 175:1575.
Darlington, P.J. et al. (2005) J. Immunol. 175:996.
Platt, A.M. et al. (2010) J. Immunol. 185:1558.
Wing, K. et al. (2008) Science 322:271.
Friedline, R.H. et al. (2009) J. Exp. Med. 206:421.
Jain, N. et al. (2010) Proc. Natl. Acad. Sci. USA 107:1524.

Long Name

Cytotoxic T-lymphocyte-associated Molecule 4

Entrez Gene IDs

1493 (Human); 12477 (Mouse); 403696 (Canine); 102115124 (Cynomolgus Monkey)

Alternate Names

CD; CD152 antigen; CD152; CD152IDDM12; CD28; celiac disease 3; CELIAC3; CTLA4; CTLA-4; cytotoxic T-lymphocyte antigen 4; cytotoxic T-lymphocyte protein 4; Cytotoxic T-lymphocyte-associated antigen 4; cytotoxic T-lymphocyte-associated protein 4; cytotoxic T-lymphocyte-associated serine esterase-4; GRD4; GSE; ICOS; ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4

Related Research Areas

Citations for Recombinant Human CTLA-4 Fc Chimera His-tag Protein

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

8 Citations: Showing 1 - 8
Filter your results:

Filter by:

CD25+FOXP3+CD45RA- regulatory T-cell infiltration as a prognostic biomarker for endometrial carcinoma
Authors: Suto, A;Minaguchi, T;Qi, N;Fujieda, K;Itagaki, H;Tenjimbayashi, Y;Shikama, A;Tasaka, N;Akiyama, A;Nakao, S;Nakahashi-Oda, C;Kobayashi, Y;Shibuya, A;Satoh, T;
BMC cancer
Species: Human
Sample Types: Whole Tissue
Applications: Immunohistochemistry
Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells
Authors: BD Hock, SA MacPherson, JL McKenzie
PLoS ONE, 2017-03-03;12(3):e0172858.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
Cell-extrinsic CTLA4-mediated regulation of dendritic cell maturation depends on STAT3.
Authors: Kowalczyk A, D'Souza C, Zhang L
Eur J Immunol, 2014-01-22;44(4):1143-55.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers.
Authors: Steidl C, Shah SP, Woolcock BW
Nature, 2011-03-02;471(7338):377-81.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement.
Authors: Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, Chapoval AI
Blood, 2010-06-02;116(10):1726-33.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysema.
Authors: Shan M, Cheng HF, Song LZ
Sci Transl Med, 2009-10-28;1(4):4ra10.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
The soluble forms of CD28, CD86 and CTLA-4 constitute possible immunological markers in patients with abdominal aortic aneurysm.
Authors: Sakthivel P, Shively V, Kakoulidou M
J. Intern. Med., 2007-04-01;261(4):399-407.
Applications: ELISA (Standard)
Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells.
Authors: Lazetic S, Leong SR, Chang JC, Ong R, Dawes G, Punnonen J
J. Biol. Chem., 2002-08-06;277(41):38660-8.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry